Chain Biotechnology Limited

CHAIN Biotechnology, a Nottingham-based biotech company and Dr Kelsey Jones, a Senior Research Fellow at University of Oxford plan to collaborate on a two-year project to develop a new type of vaccine to immunise against human rotavirus (HRV) infection. The vaccine should be highly effective for malnourished children susceptible to Childhood Diarrhoeal Di...

CHAIN Biotechnology, a Nottingham-based biotech company has developed a way to deliver therapeutics including vaccines to the colon by genetic engineering a harmless microbe called Clostridium butyricum – referred to as the CADD platform. CHAIN has engineered the bacterium to produce antigenic peptides. The bacteria are delivered orally, in a spore-form, ...

To incorporate specialist gut modelling expertise into the technology platform which delivers therapeutics directly to the gut thus accelerating time to market for a range of novel live biotherapeutic products.

"HPV is the most commonly sexually transmitted infection with over two-thirds of the population infected at some stage during life. Most infections are cleared without symptoms within a few months; however, infections with high risk types of HPV can lead to development of cancer in for example the cervix. Vaccination against these high-risk types is now a...

"The gut microbiome, the collection of bacteria, viruses and fungi inhabiting the human gastrointestinal tract, has a profound impact on the development and maintenance of a healthy immune system. From birth, the microbiome influences how the human immune system responds to resident and invading microbes, which in turn influences our susceptibility to com...

"The gut microbiome is a pharmacologically active tissue controlling infection, inflammation, receptor signalling, hormone secretion and central nervous system signalling. These events have significant impacts on patient health and wellbeing (Nature Special Review, June 2012). The importance of the gut microbiome in both health and disease is now widely r...

CHAIN Biotechnology Ltd. and the University of Nottingham are developing Clostridia bacteria for the healthcare market targeting C. difficile infections and chronic diseases like inflammatory bowel disease. The bug is a live biotherapeutic product. Success on the project will transform existing treatments for chronic gut-related diseases benefiting the li...

More than $4T of products are made currently by petrochemical (oil) derived chemical processes and only 5 % of these potentially “addressable markets” have been explored using biological approaches. There exists huge potential to reduce greenhouse gas emissions and oil dependency by further harnessing the power of Biology. Fermentation of engineered bacte...

In this project, researchers from CHAIN and the University of Nottingham aim to develop process technology that utilises methanotrophic bacteria to ferment methane into valuable nutritional supplements (lipids) for animal feed. Methane is a low cost and sustainable feedstock that can be produced from fracking or from a variety of renewable sources, includ...

CHAIN Biotech aims to produce high value fine chemicals (3-hydroxbutyric acid and ethyl-3-hydroxybutyrate) at costs lower then current chemical sysnthesis methods. By using microbial fermentation and renewable feedstock we also address key environmental and sustainability concerns. CHAIN has identified a new nutracetical market opportunity with TS who req...

Certain molecules used within industrially manufactured products not only have to be highly purified but also be of a specific structural composition. ‘Chiral’ molecules exist in two forms (scientifically called enantiomers and referred to as the S or R form) that are mirror images of one another and although the same by atomic composition are not always ...